Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship

The Society of Nuclear Medicine and Molecular Imaging is pleased to announce the recipients of the 2018-2020 SNMMI Wagner-Torizuka Fellowship.

24 Sep 2018

New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer

A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus-related head and neck cancer.

24 Sep 2018

Experts to present research on prevention, management of dysphagia at international conference

Over 800 delegates from 46 countries will attend the 8th annual European Society for Swallowing Disorders Congress taking place in Dublin next week to hear about new developments in swallowing disorder research.

19 Sep 2018

Study provides complete picture of HPV virus-head and neck cancer connections

Human papillomavirus is widely known to cause nearly all cases of cervical cancer. However, you might not know that HPV also causes 70 percent of oropharyngeal cancer, a subset of head and neck cancers that affect the mouth, tongue, and tonsils.

12 Sep 2018

New nuclear medicine imaging method could help diagnose widespread tumors

A new nuclear medicine imaging method could help diagnose widespread tumors, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy.

6 Sep 2018

Five microRNAs predict course, recurrence of HPV-negative head and neck cancer

A new method predicts the course of HPV-negative head and neck cancer after radiation chemotherapy.

4 Sep 2018

Researchers work to create humanized mouse model to test immunotherapies

If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug's effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies.

24 Aug 2018

New drug shows potential to prevent painful side effect of therapy

About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.

20 Aug 2018

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Patients with a greater than 10 pack/year history of smoking tend to develop an especially dangerous form of head and neck squamous cell cancer for which prognosis remains poor and treatments have changed little during the past two decades.

14 Aug 2018

Childhood trauma associated with anxiety and depression in adults with head and neck cancer

Among individuals with head and neck cancer, those who experienced childhood trauma were more likely to have advanced cancer, to have higher alcohol consumption, and to experience symptoms of anxiety and depression.

6 Aug 2018

UC Davis expert explains about surge in HPV-related throat cancer

Humanpapilloma virus is now the leading cause of certain types of throat cancer. Dr. Michael Moore, director of head and neck surgery at UC Davis and an HPV-related cancer expert, answers some tough questions about the trend and what can be done about it.

1 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Researchers develop simple blood test to predict likely spread of rare cancer

New QUT research has shed fresh light on how head and neck cancer spreads to other organs and researchers are developing a simple blood test to tell doctors which patients are at risk of spread long before conventional imaging can.

9 Jul 2018

Researchers develop new methods for studying evolution of cancer treatment resistance

New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center.

3 Jul 2018

New medication may treat chemotherapy, radiotherapy-induced oral mucositis

Researchers from the University of Granada have developed new medication which could help to treat and prevent chemotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients.

30 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Colorado researchers suggest new combination therapy for advanced head and neck cancer

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab.

7 Jun 2018

UD researchers examine connection between DNA replication in HPV and cancer

A pair of researchers from the University of Delaware Department of Medical and Molecular Sciences are investigating genetic variations in DNA replication of human papillomaviruses and its correlation with HPV-related cancers.

23 May 2018